Background: Vitronectin is an abundant plasma glycoprotein identified also as a part of extracellular matrix. Vitronectin is substantially enriched at sites of injured, fibrosing, inflamed, and tumor tissues where it is believed to be involved in wound healing and tissue remodeling. Little is known about the mechanism of vitronectin localization into the damaged tissues.
Introduction
Apoptosis and necrosis represent two fundamental types of cell death. While necrosis is usually viewed as a more or less passive cell rupture caused by excessive exogenous damage, apoptosis is an active process consisting of highly coordinated molecular events leading to a sequence of morphological changes and is accompanied by modifications of the cellular surface. The cell loses its surface anti-phagocytic ''don't-eat-me'' signals (mediated mostly by CD31 and CD47 glycoproteins) and exposes ligands designating the cell for phagocytosis (e.g. phosphatidylserine) [1, 2] . Moreover, several extracellular molecules bind to the apoptotic cells (e.g. MFG-E8, TSP-1, complement factors) facilitating phagocytosis [1] [2] [3] . Importantly, the early apoptotic cells preserve their plasma membrane integrity to retain the potentially harmful cellular contents inside. If not successfully taken up by phagocytes, apoptotic cells proceed to the phase of late apoptosis (termed also secondary necrosis) when the plasma membrane becomes permeable for small molecules (e.g. propidium iodide (PI)) and subsequently also for macromolecules (proteins) [4] . The leakage of intracellular molecules during secondary necrosis provokes an inflammatory response, explaining why defective apoptotic cell clearance is associated with autoimmune diseases [3] .
Reagents specifically recognizing the cells at particular stages of apoptosis can be useful research and diagnostic tools. A monoclonal antibody 2E12 has been reported to recognize a subset of apoptotic cells in culture [5, 6] . However, the precise identity of this subset as well as the molecule recognized by this antibody have remained unknown. Here we show that the 2E12 antibody recognizes bovine serum protein vitronectin (originating from cell culture medium) bound to the late apoptotic cells.
Vitronectin is a major plasma glycoprotein produced mainly in the liver where it is released into the circulation [7, 8] . It is also a part of extracellular matrix, substantially enriched at sites of injured, fibrosing, inflamed, and cancer tissue [8] [9] [10] [11] [12] .
Vitronectin was initially described as an inhibitor of complement terminal pathway and a regulator of blood homeostasis [13] [14] [15] . In addition, it contributes to tissue remodeling and healing by regulation of proteolysis, cell adhesion, migration, and survival in the injured tissue [10, [15] [16] [17] [18] [19] [20] [21] [22] . Moreover, vitronectin probably enhances migration of leukocytes into the stressed tissue [10, 19, 23] . On the other hand, vitronectin also stimulates tumor invasiveness and contributes to the development of chronic tissue injuries [15, 24, 25] . Known binding partners mediating cell interactions with vitronectin-containing tissues include integrins (a V b 3 , a V b 5 , a V b 1 , a V b 6 , a V b 8 , and aIIbb 3 ) and the urokinase receptor. In contrast, the mechanism of the transport and deposition of vitronectin in the stressed tissues remains still incompletely understood [8, 15] .
Here we bring evidence that vitronectin binds to an intracellular component of cells in the latest stage of apoptosis and of necrotic cells in vitro as well as in vivo, which could represent an important mechanism facilitating vitronectin incorporation into the sites of tissue injury.
Materials and Methods

Antibodies and proteins
Antibodies to the following antigens were used: human vitronectin (VN58-1, mouse, Abcam, Cambridge, MA, USA), human albumin (AL-01, mouse, Exbio, Vestec, Czech Republic), human cytokeratin-Alexa Fluor 488 (pan-reactive, Exbio), human vimentin-Dy-547 (Exbio), bovine vitronectin (rabbit, Acris Antibodies, Herford, Germany), mouse vitronectin (347317, rat, R&D Systems, Minneapolis, MN, USA), mouse Ig-HRP (goat, Bio-Rad, Hercules, CA, USA), rabbit Ig-HRP (goat, Bio-Rad), mouse IgAlexa Fluor 488 (goat, Invitrogene, Carlsbad, CA, USA), mouse Ig-Alexa Fluor 647 (goat, Invitrogen), and rat Ig-Allophycocyanin (APC) (goat, BD Bioscience, Franklin Lakes, NJ, USA). The following isotype matched controls were used: Rat IgG2a (eBioscience, San Diego, CA, USA) and anti-HLA-DR (mouse IgG1, MEM-12, in house). Following proteins and peptides were used: human vitronectin (Technoclone, Dorking, UK), biotinylated human vitronectin (Cell Sciences, Sharon, MA, USA), bovine vitronectin (Sigma-Aldrich, St. Louis, MO, USA), RGD peptide (Sigma-Aldrich), streptavidin-Alexa Fluor 488 (Invitrogene), Annexin-V-FITC, Annexin-V-Dy647 (both Apronex, Prague, Czech Republic). Mouse monoclonal antibody 2E12 (IgG1) was described previously [5] .
Cell culture
Human cell lines Jurkat (American Type Culture Collection, Manassas, VA, USA), HeLa (provided by D. Stanek, IMG, Prague, Czech Republic), JCaM2.5 (A. Weiss, University of California, San Francisco, CA, USA), Ramos, HL-60 (both American Type Culture Collection), chicken cell line DT40 (J. Wienands, University of Göttingen, Germany), rabbit cell line 240E1 (K. Knight, Loyola University Chicago, Maywood, IL, USA), mouse cell lines SP2/0 (American Type Culture Collection), P815 (H. Stockinger, Medical University of Vienna, Austria) were cultivated in RPMI 1640 medium containing 10% fetal bovine serum (FBS), 2 mM glutamine, 20 mg/ml gentamycin, 50 mg/ml streptomycin, and 10 4 U/ml penicillin at 37uC in 5% CO 2 . A green fluorescent protein (GFP) expressing Jurkat cell line (provided by M. Hrdinka, IMG, Prague) was prepared by electroporation (250 V, 950 mF) of pZRD (15 mg) vector [26] in RMPI (300 ml) using a GenePulser electroporator (Bio-Rad Laboratories, Hercules, CA, USA) followed by zeocin selection (200 mg/ml, Invitrogen).
Apoptosis was induced by TRAIL ligand (300 ng/ml, Apronex) or camptothecin (1 mM, Sigma-Aldrich) for the indicated time period. Inhibition of apoptosis was performed with pan-caspase inhibitor Z-VAD-FMK (10 mM, Enzo Life Sciences, Inc., Farmingdale, NY, USA). Necrosis was induced by incubation at 65uC for 40 minutes or by hydrogen peroxide (2 mM) in combination with Z-VAD-FMK (10 mM).
Flow cytometry and confocal microscopy
Viable, apoptotic, or necrotic Jurkat cells were stained with a primary antibody followed by a corresponding secondary antibody (both in PBS/1% BSA, on ice, 30 min). Alternatively, cells were incubated with biotinylated vitronectin (3.6 mg/ml) followed by streptavidin-Alexa Fluor 488 (both in PBS/1% BSA, on ice, 30 min). Stages of cell death were examined by staining with Annexin-V, PI (1 mM, Sigma-Aldrich), and/or Hoechst 34580 (2 mg/ml, Invitrogen) (Annexin binding buffer or PBS/1% BSA, on ice, 30 min). For DNA content analysis, the cells were incubated with Hoechst 34580 (5 mg/ml, 37uC, 20 min). For microscopy, cells were transferred into Lab-Tek chambers (Thermo Fisher Scientific, Waltham, USA) in Annexin binding buffer.
HeLa cells were fixed (PBS/4% formaldehyde), permeabilized, and blocked (PBS/5% BSA/0.3% Triton-X 100). The cells were incubated with human serum at 37uC followed by staining with primary and secondary antibodies at room temperature. Serum and antibodies were diluted in PBS/1% BSA/0.3% Triton-X 100. For microscopy, the cells were stained with Hoechst 34580 (2 mg/ ml) for 5 minutes.
Spleens and thymi were collected from healthy 8-9 weeks old C57Bl/6j mice (IMG Animal Facility). Single-cell thymocyte or splenocyte suspensions were prepared followed by erythrocyte lysis in ACK buffer. Approximately 2610 6 cells were stained with antivitronectin or isotype matched control antibodies followed by incubation with APC-conjugated secondary antibody (PBS/20% goat serum, on ice, 30 min). Flow cytometry samples were analyzed on LSRII or FACScalibur apparatus (BD Biosciences). Data were analyzed using FlowJo software (TreeStar, San Carlos, CA, USA). Images were acquired with a Leica SP5 confocal microscope using a 1006 objective lens (Leica Microsystems, Mannheim, Germany). Data were analyzed using LAS AF 2.00 software (Leica).
Quantification of GFP release to the medium
4610
6 wild type or GFP-expressing Jurkat cells were transferred to fresh RPMI/10% FBS at high cell density (2.5610 6 cells/ml) and apoptosis was induced by camptothecin. At indicated time points, 150 ml of the suspension was taken, centrifuged, and the cell free supernatant was kept in 37uC. After the collection of all samples, fluorescence intensity (excitation 475 nm, emission 510 nm) of each sample (100 ml) was measured by InfiniteM200 microplate reader (Tecan Group Ldt., Mannedorf, Switzerland). The GFP fluorescence in medium was obtained by subtraction of the background fluorescence of the respective samples from GFPnegative Jurkat cultures.
Immunoisolation
2E12 or isotype matched control antibodies were covalently bound to CNBr-activated Sepharose (Sigma-Aldrich) according to the manufacturer's instructions. Immunoaffinity chromatography was performed at 4uC on minicolumns containing 40 ml of the immunosorbent. FBS (100 ml) was applied at the top of the minicolumn followed by PBS wash (400 ml). The adsorbed proteins were eluted with 80 ml of 0.1 M triethanolamine (pH 11.5). Subsequently, pH of the eluted fraction was adjusted with 10 ml 1 M Tris/HCl (pH 8.2). Finally, the material was mixed 1:1 with 26 concentrated Laemmli sample buffer (nonreducing or reducing with final 0.5% dithiothreitol) and subjected to SDS-PAGE followed by Coomassie Brilliant Blue R-250 (BioRad) staining or immunoblotting.
Mass spectrometry analysis
Preparation of the sample and analysis by an ion trap mass spectrometer (LCQ DECA , ThermoElectron, Waltham, MA, USA) was performed as described previously [27] . The instrument was set to acquire a full MS scan between 350-1800 m/z followed by MS/MS scan of the most intense ion from the preceding scan. The MS/MS data were searched against NCBI non-redundant database with SEQUEST software (Thermo Fisher Scientific) as described previously [28] . 
Binding of vitronectin to red blood cells
Results
2E12 antibody specifically binds late apoptotic cells cultured in the presence of bovine serum
Monoclonal antibody 2E12 recognized a subpopulation of Jurkat T cells in culture, as revealed by flow cytometry (Fig. 1A) . The frequency of 2E12-positive cells varied, depending on the viability of the particular culture. Overgrown cultures (approx. 2610 6 cells/ml) contained more cells stained with 2E12 than cultures in optimal growth conditions (,10 6 cells/ml) ( Fig. 1A-B ). The 2E12-positive cells exhibited features of cell death as indicated by forward and side scatter analysis and Annexin-V staining ( Fig. 1A-B) . In contrast to previously published data [5] , these cells were stained with PI, indicating that the plasma membrane was not intact (Fig. 1B) . However, cells, that were most intensively stained with PI, were 2E12-negative. The intermediate PI signal of the 2E12-positive cells can be explained by low DNA content as shown by Hoechst 34580 staining (Fig. 1B) .
We induced apoptosis in Jurkat cells and monitored them using Annexin-V, PI, and 2E12 staining over time. We distinguished three populations of apoptotic cells:
2 , and Annexin-V + /PI + /2E12 + (Fig. 1C) . The Annexin-V + /PI 2 population that peaked early after apoptosis induction and diminished over time, was identified as early apoptotic cells. Secondary necrotic cells defined as Annexin-V + / PI + appeared later. Interestingly, the increase of Annexin-V + /PI + / 2E12
+ cells was observed after 48 hours, suggesting that the 2E12-positive cells represent the latest stage of apoptosis progression.
We performed a comparison between the 2E12-positivity and intracellular protein release after apoptosis induction over time. Jurkat cell line producing cytosolic GFP was subjected to apoptosis induction with camptothecin at high cell density. The kinetics of the GFP release to the medium was strikingly similar to the increase of the percentage of the 2E12-positive cells over time (Fig. 1D ). This observation suggests that the cells stained with 2E12 are the source of GFP released to the medium. The 2E12 antibody obviously recognizes cells with severely damaged plasma membrane, permeable for large molecules like proteins.
We tested six cell lines of different origin (human, chicken, rabbit, and mouse) cultured in the presence of fetal bovine serum (FBS) for 2E12 positivity. In all cases a hypodiploid 2E12-positive population was detected (Fig. S1 ). This led us to hypothesize that the 2E12 antibody might recognize a bovine serum component specifically bound to late apoptotic cells. Thus, we prepared late apoptotic Jurkat cells in serum-free medium followed by a short incubation in FBS prior to 2E12 staining. The serum-treated cells, but not cells held in serum-free conditions, became 2E12-positive (Fig. 1E) , which pointed to the serum origin of the molecule recognized by the 2E12 antibody. Extension of this assay to sera from different species revealed that short incubation in bovine or goat but not in rat, guinea pig, or human sera resulted in recognition of the late apoptotic cells by the 2E12 antibody (Fig. 1F ).
2E12 antibody recognizes bovine vitronectin
To identify the bovine serum component recognized by the 2E12 antibody, we subjected the serum to immunoisolation on immobilized 2E12 antibody. Separation of the immunoprecipitated material by SDS-PAGE under non-reducing conditions followed by Coomassie Blue protein staining detected a single major protein (ca 70-80 kDa) that was immunoisolated using the 2E12 antibody but not an isotype matched control antibody ( Fig. 2A) . The stained zone was cut from the gel, trypsin digested, and analyzed by tandem mass spectrometry. Bovine vitronectin (accession number 78045497) was the only protein identified in the sample. The final protein coverage was 39% with 15 peptides spread over the whole protein sequence (AA 38 to 476). To confirm that 2E12 antibody is specific for bovine vitronectin, we immunoblotted purified vitronectin standard side by side with the material immunoisolated by means of the 2E12 antibody. Both 2E12 antibody and a commercial polyclonal antibody to bovine vitronectin stained the immunoisolated material as well as the vitronectin standard (Fig. 2B) . Furthermore, when unseparated FBS was subjected to Western blotting, 2E12 antibody detected only a doublet corresponding by m.w. to vitronectin and not any other of the multiple bovine serum components (not shown). Thus, it can be safely concluded that the 2E12 antibody recognizes bovine vitronectin and that the material immunoisolated from FBS by means of the 2E12 antibody contains vitronectin (Fig. 2B) . The presence of the two bands observed in the Western blots is caused by reduction of the sample with dithiothreitol that reveals the previously described single-chain (75 kDa) and two-chain (65+10 kDa) vitronectin forms [7] .
Vitronectin binds late apoptotic cells directly
After we identified that bovine serum vitronectin binds to late apoptotic cells, we decided to study the interaction in more detail. We switched to a purely human model system to avoid any potential complications resulting from interspecies incompatibilities at the molecular level and repeated the vitronectin binding assay using Jurkat cells, human serum, and antibody to human vitronectin. The late apoptotic cells were again recognized by antivitronectin antibody only after incubation in human serum (Fig. 3A) . The percentage of human vitronectin-positive cells increased after apoptosis induction when cultivated in human serum-containing medium (Fig. S2 ) and followed similar kinetics to 2E12-positive cells in RMPI/10% FBS (Fig. 1C) . To test whether binding to late apoptotic cells is a specific feature of vitronectin, we performed staining of late apoptotic cells with antibodies to human vitronectin and human albumin. Although albumin is 300 times more abundant than vitronectin in plasma [29] and the antialbumin antibody produced a much stronger signal than the antivitronectin antibody in ELISA assay on human serum (not shown), the signal produced by anti-albumin antibody on the serumincubated late apoptotic cells was negligible compared to the antivitronectin antibody (Fig. 3B) . This indicated the specificity of the vitronectin binding. Given the multiplicity of known vitronectinbinding partners in plasma [7] , it was unclear whether vitronectin binds the late apoptotic cells directly or uses another serum component as a molecular bridge. We incubated the late apoptotic cells in serum-free medium with various concentrations of purified vitronectin. Vitronectin bound to the cells in a dose dependent manner indicating a direct interaction between vitronectin and the late apoptotic cells (Fig. 3C) .
Live cells are able to interact with vitronectin via several integrin receptors. However, high concentrations of EDTA or the integrin-blocking peptide (RGD) did not prevent binding of serum vitronectin to late apoptotic cells, excluding the possibility that the interaction was mediated by integrins (Fig. 3D) . Surprisingly, both EDTA and the RGD peptide even enhanced the signal intensity after anti-vitronectin antibody staining. On the other hand, heparin, a well established vitronectin interaction partner [29] , was able to block binding of serum vitronectin to late apoptotic cells in a dose dependent manner (Fig. 3D) . A possible explanation of this observation could be that heparin binding prevents recognition of the vitronectin molecule by the antibody. Thus, we prepared biotinylated red blood cells with bound biotinylated vitronectin using streptavidin as a bridge and examined the ability of anti-vitronectin antibody to recognize vitronectin in the presence of heparin. In this assay, heparin had no effect on the signal intensity (Fig. 3E) , supporting the conclusion that heparin blocks vitronectin binding to the late apoptotic cells.
Vitronectin binds inside the damaged cells
Late apoptotic cells share many features with necrotic cells (e.g. damaged plasma membrane). We tested the ability of serum vitronectin to bind Jurkat cells after heat-induced necrosis. Necrotic, but not viable, cells became positive for vitronectin after incubation in human serum (Fig. 4A) .
We employed confocal microscopy to see whether vitronectin binds to the surface or inside the late apoptotic cells. Antivitronectin staining combined with Annexin-V membrane staining revealed clear surface localization of Annexin-V contrasting with diffuse intracellular staining for vitronectin in the late apoptotic cells and apoptotic bodies (Fig. 4B) . As the cells were not fixed or permeabilized prior to the staining, the intracellular vitronectin signal implied that the late apoptotic cell membranes were permeable for vitronectin as well as for the antibodies. Regions of apoptotic fragmented nuclei stained by Hoechst 34508 were devoid of vitronectin indicating that vitronectin bound to cytoplasmic structures inside the late apoptotic cells (Fig. 4B) . The vitronectin staining produced no signal when the preincubation in human serum was omitted; thus confirming the signal specificity (not shown). Additionally, microscopy also supported our flow cytometric data (Fig. 1B) demonstrating that vitronectin-positive cells contain only small amounts of DNA (Fig. S3 ).
Intermediate filaments do not mediate vitronectin binding
Since we detected vitronectin inside the ruptured apoptotic and necrotic cells, we hypothesized that the vitronectin binding partner might be present inside intact viable cells, but it is inaccessible to vitronectin due to the barrier represented by the plasma membrane. We tested the hypothesis using viable HeLa cells after detergent permeabilization. As expected, fixed and permeabilized HeLa cells interacted with human serum vitronectin in a heparin sensitive manner (Fig. 5A) .
As vitronectin was shown to interact with vimentin and cytokeratins in vitro [30, 31] , intermediate filament proteins seemed to be good candidates for vitronectin binding. However, confocal microscopy showed a diffuse cytoplasmic pattern of vitronectin staining in permeabilized HeLa cells after incubation in human serum. Moreover, vitronectin did not co-localize with vimentin or cytokeratins (Fig. 5B) indicating that vitronectin interacts with a cytoplasmic structure different from intermediate filament proteins.
Vitronectin binds late apoptotic/necrotic cells in vivo
Experiments performed on cell cultures showed that serum vitronectin bound to the late apoptotic and necrotic cells in vitro. To elucidate whether vitronectin binds to the dead cells in vivo, we analyzed murine splenocytes and thymocytes in a four-colour flow cytometry assay. The cells were stained simultaneously with Hoechst 34580, PI, and Annexin-V for identification of late apoptotic/necrotic cells and with a rat antibody to mouse vitronectin. The splenocyte cell suspension contained about 1-2% of Hoechst 34580/PI/Annexin-V-triple positive necrotic/ late apoptotic cells. Majority of these cells were positive for vitronectin, in contrast to essentially vitronectin-negative viable splenocytes (Fig. 6A) . Thymus contained about 0.5% of late apoptotic/necrotic cells. About one quarter of these cells in thymus were positive for vitronectin whereas viable thymocytes were not stained with the anti-vitronectin antibody at all (Fig. 6B) . The staining procedure was performed in the presence cytometry. (F) Cells were prepared as in (E) except that the apoptotic cells were incubated with 50% bovine, rat, guinea pig, goat, or human sera or left untreated prior to 2E12 staining and analysis. Mean 6 SD, n = 3. RMFI, relative mean fluorescence intensity. doi:10.1371/journal.pone.0019243.g001 of 20% goat serum, which was not recognized by the antibody to mouse vitronectin (not shown). These results support the conclusion that vitronectin binds the late apoptotic/necrotic cells also in vivo.
Vitronectin as a tool for monitoring of cell death
As demonstrated above, vitronectin binds to cells with ruptured membrane in vitro and in vivo. When cells die in the presence of serum, the antibody recognizing vitronectin of the respective species can be used for detection of the terminal cell death phase (Fig. 1C, Fig. S2) . If the cells are cultivated in the absence of vitronectin, a short incubation in the presence of serum or purified vitronectin must be included prior to the staining procedure (e.g. Fig 3A-C) . Based on these results we developed an easy two-step cytofluorometric method for evaluation of the cell membrane integrity that works in all conditions regardless of the cultivation medium.
We induced apoptosis of Jurkat cells with TRAIL in FBScontaining medium for 24 hours. The cells were stained with biotinylated vitronectin which was detected with streptavidin conjugated with Alexa Fluor 488 dye followed by flow cytometry. The number of vitronectin-positive cells increased after the apoptosis induction, showing that the method is compatible with cultivation in the presence of serum (Fig. 7A) . Subsequently, we used this method for monitoring of cell cultures after apoptosis induction over time (Fig. 7B) . The percentage of vitronectin- 
/PI
2 ) nor vitronectin-stained cells appeared when the TRAIL-induced apoptosis was blocked with pan-caspase inhibitor Z-VAD, confirming that the vitronectinpositive cells were apoptotic.
As shown above, heat-induced necrotic cells become vitronectin-positive (Fig. 4A) . However, necrosis can be induced by a milder stimulus that does not destroy cells immediately. Thus, we induced necrosis with hydrogen peroxide in combination with Z-VAD (to prevent possible apoptosis) and compared the cell death progression with TRAIL-induced apoptosis under serum-free conditions. Interestingly, the percentage of vitronectin-stained cells increased much more rapidly in the necrotic culture than in the apoptotic one (Fig. 7C) . A triple staining with Annexin-V-Dy647, propidium iodide, and vitronectin showed that the character of the Annexin-V-positive cells differs substantially between the apoptotic and necrotic cells 18 hours after the particular cell death commitment (Fig. 7D) . Annexin-V-positive apoptotic cells included comparable amounts of early apoptotic (PI 2 /Vn 2 ), late apoptotic (PI + /Vn 2 ), and 'very late' apoptotic (PI + /Vn high ) cells. In contrast, Annexin-V-positive necrotic cells were mostly vitronectin highly positive and contained less PI + /Vn 2 and only very few PI 2 /Vn 2 cells. These results suggest that the progression of cell death resulting in complete membrane permeabilization is much faster in necrosis than in apoptosis. 
Discussion
2E12 monoclonal antibody was reported to stain a subset of late apoptotic cells cultured in vitro [5] [6] . We identified the antigen recognized by 2E12 antibody as a bovine serum protein vitronectin that binds to apoptotic cells of various origin. Using a human T-cell line Jurkat and human vitronectin, we found that purified vitronectin binds late apoptotic cells in a dose-dependent manner. This binding could be inhibited by heparin. Confocal microscopy revealed that vitronectin binds inside the cells with severely damaged membrane. Moreover, vitronectin was detected in dead cells in mouse spleen and thymus suggesting that vitronectin binds necrotic cells and cells at the terminal stage of apoptosis in vivo.
Flow cytometry has been widely used to assess viability, apoptosis, and/or necrosis on a single cell basis [32] . A common method for detection of apoptotic cells is based on staining with Annexin-V and a DNA-binding dye that does not penetrate intact cell membrane (e.g. PI). Annexin-V-positive and PI-negative cells are considered as ''early apoptotic'' while the double positive cells are classified as ''late apoptotic'' or ''necrotic''. However, it has been documented that the loss of the membrane integrity is a gradual process. First, the membrane of a late apoptotic cell becomes permeable for small molecules (PI) and subsequently opens also for macromolecules [4, [33] [34] [35] . The latter phase of membrane damage is usually monitored as a leakage of lactate dehydrogenase or other intracellular proteins using enzymatic assays or immunoblotting. Our observations suggest that a simple flow cytometry approach based on vitronectin staining can be used to distinguish between the two subsets of late apoptotic cells on a single cell level. Such classification of the apoptotic stages could be biologically important. In contrast to vitronectin-positive cells, the PI + /Vn 2 cells can still retain macromolecules that could induce immunogenic or inflammatory response in case of their escape [4] . We used this method to reveal that necrosis induced by oxidative stress (hydrogen peroxide) or heating leads to complete membrane permeabilization much faster than apoptosis. Apoptotic cells are apparently able to keep their membranes non-permeable for proteins and other macromolecules for some time even after they become permeable for small charged molecules like propidium iodide. Thus, they can extend the time needed for their clearance before the potential auto-antigens are released into the body. In contrast, necrotic cells become permeable for proteins either immediately or shortly after the onset of necrosis.
Vitronectin is an abundant plasma glycoprotein and is a part of the extracellular matrix [7, 8, 14, 15] . While the plasma vitronectin is produced mainly by the liver, the origin of the tissue vitronectin is less clear [8] . Most probably the tissue vitronectin originates mainly from the plasma vitronectin that is translocated across endothelium via active transcytosis [8, 36, 37] . Alternatively, vitronectin could be produced locally in the tissue. This is supported by the detection of vitronectin mRNA in several tissues albeit at much lower level than in the liver [8] . Vitronectin is substantially enriched in the sites of inflamed, injured, necrotic, and cancer tissues including cirrhotic liver, atherosclerotic plaques, injured skin, Alzheimer plaques, myocardial infarction, and colorectal carcinoma [8] [9] [10] [11] [12] 15, 25, 29, 31, [38] [39] [40] [41] . Interestingly, atherosclerosis and Alzheimer disease are also associated with defects in apoptotic cell clearance [3] .
Little is known about the mechanisms regulating the delivery of vitronectin specifically into the sites of injured tissue. Two possible explanations were suggested: (1) vitronectin leakage from capillaries at the sites of injury and (2) an interaction between vitronectin and a component specifically present in the stressed tissue [8] . Here we show that vitronectin binds to necrotic and late apoptotic cells in cell culture and in vivo. This supports the model that vitronectin incorporation into the sites of injured, stressed, and, possibly, also cancer tissue is at least partially dependent on the interactions with a cytoplasmic component exposed after tissue injury.
Vitronectin was shown to bind to in vitro prepared keratin bodies and to keratinocyte derived Civatte bodies in patients suffering from lichen ruber planus [30, 42] . Moreover, vitronectin was shown to interact with purified vimentin and with vimentin exposed on the surface of activated platelets [31, 43] . However, we show here that the intracellular vitronectin-interacting structure is diffusely distributed in the cytoplasm of viable cells and does not co-localize with vimentin or cytokeratine filaments. Thus, the binding of vitronectin to necrotic and late apoptotic cells is apparently mediated mainly by a so far unidentified component different from the intermediate cytoskeletal proteins.
Among numerous vitronectin binding receptors, a V b 3 , a V b 5 integrins and the urokinase receptor are involved in the recognition and engulfment of apoptotic cells by phagocytes [2, 44, 45] . However, other ligands of these receptors, including milk fat globule-EGF factor 8 and thrombospondin, were found to mediate phagocytosis of apoptotic cells [3, 46, 47] while there was only indirect evidence for possible vitronectin involvement [48] [49] [50] . Despite numerous attempts, we did not observe any effects of vitronectin opsonization on phagocytosis of the late apoptotic cells by human monocytes, macrophages, or dendritic cells (not shown). Accordingly, depletion of vitronectin from bovine serum also did not induce any changes in phagocytosis of the late apoptotic cells (not shown).
In conclusion, our observations that vitronectin binding does not serve as an opsonization step to facilitate phagocytosis indicates that this interaction may be rather relevant for other biological roles of vitronectin in regeneration processes in injured tissues (i.e. tissue remodeling, cell survival, and inflammation) that were documented in several previously published studies [16] [17] [18] 21, 22] . 
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